Financial News
Articles published by Aurinia Pharmaceuticals Inc.
Aurinia Commends 2024 Updated ACR Guidelines for Screening, Treatment, and Management of Lupus Nephritis
November 18, 2024
Via Business Wire
Tickers
AUPH
Aurinia to Participate in Jefferies London Healthcare Conference
November 14, 2024
Via Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals Appoints Craig Johnson to Board of Directors to Support Next Phase of Growth
November 07, 2024
Via Business Wire
Tickers
AUPH
Aurinia Pharmaceuticals to Release Third Quarter Financial and Operational Results on November 7, 2024
October 30, 2024
Via Business Wire
Tickers
AUPH
Aurinia Announces Japan Approval of LUPKYNIS® (Voclosporin) to Treat Lupus Nephritis
September 24, 2024
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Via Business Wire
Tickers
AUPH
Aurinia Receives Exemptive Relief from Canadian Securities Regulators for Share Repurchase Program
February 29, 2024
Via Business Wire
Tickers
AUPH
Aurinia to Participate in Upcoming Investor Healthcare Conferences
February 27, 2024
Via Business Wire
Tickers
AUPH
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.